Ravandi F, Patel K, Luthra R. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin[J]. Cancer, 2011, 118(10):2665-2673.
Lowinger TB, Riedl B, Dunsas J, et al. Design and discovery of small molecules targeting raf-1 kinase[J]. Curr pharm Des, 2002, 8(25):2269-2278.
[9]
Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines[J]. Oncogene, 2000, 19(5):624-631.
[10]
Alvarado Y, Kantarjian HM, Luthra R, et al. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations[J]. Cancer, 2014, 120(14):2142-2149.
[11]
Hasskarl J. Sorafenib:targeting multiple tyrosine kinases in cancer[J]. Recent Results Cancer Res, 2014, 201:145-164.
[12]
Levis M1, Allebach J, Tse KF, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML[J]. Blood, 2002, 99(11):3885-3891.
